Ticker

Xtant has hired Dilon's U.S. sales team to assist in selling the HEMOBLAST ® Bellows product and penetrating the estimated $2.0 billion global addressable market for hemostatic products BELGRADE, Mont. and NEWPORT NEWS, Va.

BELGRADE, Mont., April 9, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), in partnership with the Montana Governor's Office of Community Service (GOCS), today announced support for the Threshold of Life Memorial, a statewide initiative honoring organ, eye, and tissue donors and the lives they have impacted.

Xtant Medical Holdings, Inc. (XTNT) Q4 2025 Earnings Call Transcript

Full year 2025 revenue totals $133.9 million, an increase of 14% year-over-year Xtant delivers positive net income, adjusted EBITDA and operating cash flow Total cash of $17.3 million as of December 31, 2025 with an additional $10.5 million received subsequent to year end related to divestiture BELGRADE, Mont., March 31, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical…

BELGRADE, Mont., March 25, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2025, before the start of trading on Tuesday, March 31, 2026.